Close

Provention Bio Inc. (PRVB) PT Raised to $20 at H.C. Wainwright

June 26, 2019 8:11 AM EDT
Get Alerts PRVB Hot Sheet
Price: $24.98 --0%

Rating Summary:
    2 Buy, 5 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Provention Bio Inc. (NASDAQ: PRVB) to $20.00 (from $8.00) while maintaining a Buy rating. Earlier this month, Provention Bio reported that a Phase 2 clinical trial the Teplizumab for Prevention of Type 1 Diabetes In Relatives “At-Risk” trial had yielded highly favorable results.

Selvaraju believes that the data from the company's at-risk trial is clearly meaningful enough to warrant a potential acceleration of teplizumab's progression to market entry. H.C. Wainwright revised assumptions involve the scenario that teplizumab could be filed with the FDA later this year or early next year; this could lead to market entry in 2021.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

H.C. Wainwright, FDA